Navigation Links
Harwood Feffer LLP Announces Securities Class Action Lawsuit Against Puma Biotechnology, Inc. And Advises Shareholders To Contact Harwood Feffer LLP Prior To The Lead Plaintiff Deadline
Date:6/22/2015

NEW YORK, June 22, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) announces a class action lawsuit has been filed in the United States District court for the Central District of California against Puma Biotechnology, Inc. ("Puma" or the "Company") (NYSE: PBYI), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired Puma shares between July 23, 2014 and May 13, 2015, inclusive (the "Class Period"), have until August 3, 2015 to serve as lead plaintiff in the class action. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Puma is a biopharmaceutical company that focuses on in-licensing cancer drug candidates that have already undergone or completed clinical testing. The complaint alleges that Puma made false and/or misleading statements and/or failed to disclose in violation of the securities laws that: (1) the Company's New Drug Application ("NDA") filing would be for a positive early stage breast cancer indication, instead of the previously announced metastatic breast cancer; (2) Puma would need to submit additional safety data from preclinical carcinogenicity studies with its NDA filing, which Puma did not have; (3) the additional studies required would push the timeline for filing the NDA into the first quarter of 2016; (4) the Company overstated results from its Phase III ExteNET trial; and (5) as a result of the foregoing, Puma lacked a reasonable basis for their positive statements concerning the Company's outlook, as well as the ongoing ExteNET trial. When the truth was revealed, the stock dropped causing damage to investors.

If you are a shareholder who suffered a loss during the Class Period and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

 


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of Kythera Biopharmaceuticals, Inc.
2. Harwood Feffer LLP Announces Investigation of Geron Corporation
3. Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc.
4. Harwood Feffer LLP Announces Investigation of Dietary Supplements Containing BMPEA
5. Harwood Feffer LLP Announces Investigation of Acadia Pharmaceuticals Inc.
6. Harwood Feffer LLP Announces Investigation of Advaxis, Inc.
7. Harwood Feffer LLP Announces Investigation of Avanir Pharmaceuticals, Inc.
8. Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc.
9. Harwood Feffer LLP Announces Investigation of Santarus, Inc.
10. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
11. Updated: Harwood Feffer LLP Announces Investigation of Edwards Lifesciences Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... (PRWEB) , ... July 19, 2019 , ... ... September 11-13, in Phoenix, will provide strategies to keep pathologists, laboratory professionals and ... techniques to improve outcomes and enhance patient care. , Renowned Speakers Covering ...
(Date:7/19/2019)... ... July 19, 2019 , ... Robinson Pharma, Inc., is proud to ... facilities was audited by the Safe Quality Food (SQF) Institute using an accredited certification ... Safety Code for Manufacturing, Edition 8. , The SQF Certification program is trusted by ...
(Date:7/18/2019)... ... July 18, 2019 , ... NeoTract, a wholly ... field of urology, today announced that Timothy Lesser, MD, Skyline Urology in Torrance, ... that Dr. Lesser has achieved a high level of training and experience with ...
Breaking Medicine Technology:
(Date:7/19/2019)... , ... July 19, 2019 , ... ... the appointment of Nathan Okuley as its Director of Marketing and Sales. In ... next phase of the company’s rapid growth while furthering the company’s mission of ...
(Date:7/18/2019)... ... July 18, 2019 , ... The Radiology ... Congress about new bills to protect patients from unexpected out-of-network medical bills incurred ... Surprise Medical Bills Act ( H.R. 3502 ), introduced in the U.S. House ...
(Date:7/18/2019)... ... July 18, 2019 , ... NeoTract, a wholly owned ... of urology, today announced that Garrett Matsunaga, MD, Skyline Urology in Torrance, CA ... Dr. Matsunaga has achieved a high level of training and experience with the ...
(Date:7/18/2019)... ... July 18, 2019 , ... For the fourth ... Atlanta, Magazine’s list of “Top Doctors” issue. Deutsch is a double-board-certified plastic and, ... With specialized training from MD Anderson Cancer Center and Albert Einstein, Montefiore Medical ...
(Date:7/18/2019)... ... , ... We are pleased to honor thirteen U.S. ... Rising Star ! Each year, Texas Monthly asks doctors across the state ... care. The Super Doctors research team then investigates independently. Candidates are evaluated based ...
Breaking Medicine News(10 mins):